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Summary
Nephropathic cystinosis is an autosomal recessive lyso-
somal storage disease characterized by renal failure at
10 years of age and other systemic complications. The
gene for cystinosis, CTNS, has 12 exons. Its 2.6-kb
mRNA codes for a 367–amino-acid putative cystine
transporter with seven transmembrane domains. Previ-
ously reported mutations include a 65-kb “European”
deletion involving marker D17S829 and 11 small mu-
tations. Mutation analysis of 108 American-based ne-
phropathic cystinosis patients revealed that 48 patients
(44%) were homozygous for the 65-kb deletion, 2 had
a smaller major deletion, 11 were homozygous and 3
were heterozygous for 753GrA (W138X), and 24 had
21 other mutations. In 20 patients (19%), no mutations
were found. Of 82 alleles bearing the 65-kb deletion, 38
derived from Germany, 28 from the British Isles, and 4
from Iceland. Eighteen new mutations were identified,
including the first reported missense mutations, two in-
frame deletions, and mutations in patients of African
American, Mexican, and Indian ancestry. CTNS muta-
tions are spread throughout the leader sequence, trans-
membrane, and nontransmembrane regions. According
to a cystinosis clinical severity score, homozygotes for
the 65-kb deletion and for W138X have average disease,
whereas mutations involving the first amino acids prior
to transmembrane domains are associated with mild dis-
ease. By northern blot analysis,CTNSwas not expressed
in patients homozygous for the 65-kb deletion but was
expressed in all 15 other patients tested. These data dem-
onstrate the origins of CTNS mutations in America and
provide a basis for possible molecular diagnosis in this
population.
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Introduction
Classical nephropathic or infantile cystinosis (MIM
219800) is a rare autosomal recessive disorder charac-
terized by lysosomal storage of free, nonprotein cystine
(Gahl 1986; Gahl et al. 1995). Cystinosis patients are
normal at birth but develop renal tubular Fanconi syn-
drome at 6–12 mo of age, accompanied by failure to
thrive, polyuria and polydipsia, dehydration, and hypo-
phosphatemic rickets. Photophobia and hypothyroidism
generally appear in the 1st decade of life. Glomerular
damage results in renal failure at ∼10 years of age (Gahl
et al. 1995). After renal transplantation, progressive cys-
tine storage can cause a distal vacuolar myopathy (Char-
nas et al. 1994), swallowing difficulty (Sonies et al.
1990), retinal blindness (Kaiser-Kupfer et al. 1986), di-
abetes mellitus (Fivush et al. 1987), and neurological
deterioration (Ehrich et al. 1979; Fink et al. 1989).
Milder variants of the classical disease include an inter-
mediate form with late-onset renal disease and a benign
form with corneal involvement but no renal impairment
(Gahl et al. 1995). Oral therapy with the free thiol cyste-
amine lowers the cystine content of leukocytes (Thoene
et al. 1976) and a variety of cell types, including muscle
(Gahl et al. 1992). Cysteamine has proven efficacy in
preventing renal deterioration, enhancing growth, and
obviating the need for thyroid-hormone replacement
(Gahl et al. 1987; Markello et al. 1993; Kimonis et al.
1995).
The basic defect in cystinosis is deficiency of a cystine
carrier in the lysosomal membrane (Gahl et al. 1982a,
1982b; Jonas et al. 1982). The cystine-transport system
is saturable and bidirectional (Gahl et al. 1983), and it
displays a gene-dosage effect in obligate heterozygotes
for cystinosis (Gahl et al. 1984). The therapeutic action
of cysteamine involves its reaction with cystine to pro-
duce the free thiol amino acid cysteine and the mixed
disulfide cysteine-cysteamine, both of which exit the cys-
tinotic lysosome by a process not requiring the defective
carrier system (Gahl et al. 1985; Pisoni et al. 1985).
The gene for cystinosis was first mapped to a 4-cM
region of chromosome 17p13, by linkage analysis (Cys-
tinosis Collaborative Research Group 1995). The critical
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Table 1
Severity Score Parameters
PARAMETER
SEVERITY SCORE
1 2 3
Age at onset (mo) 115 9–15 !9
Leukocyte cystine (nmol
half-cystine/mg protein)a !5 5–15 115
Fanconi syndrome index
(mmol/kg/d)b !500 500–2,000 12,000
Age at renal failure (years) 110 8–10 !8
Age at nonrenal complica-
tion (years) None x20 !20
a Not receiving cysteamine therapy. Normal value is !0.2 nmol half-
cystine/mg protein.
b Normal value is mmol/kg/d (Charnas et al. 1991).95 45
Figure 1 A, Gel-electrophoresis pattern for markers D17S829
(266 bp; denoted by “829”), within the common 65-kb deletion region,
and SBG7 (168 bp), outside the deletion region. Samples were from
a nondeletion patient (lane 1) and a deletion patient (lane 2). Lane 3
shows the size markers. B, SSCP analysis of exon 7. Lanes 2 and 3
show the normal band pattern. Lane 4 contains DNA from a patient
subsequently shown by sequencing to be homozygous for 753GrA
(W138X). DNA from a patient heterozygous for this mutation was
run in lane 1. All the lanes are from the same gel; intervening lanes
were removed.
region was progressively narrowed (Jean et al. 1996;
McDowell et al. 1996; Peters et al. 1997), and several
cystinosis patients were found to have deletions in a
specific microsatellite marker, D17S829, in the region.
Physical mapping near this deletion led to isolation of
the cystinosis gene, CTNS (Town et al. 1998; Genome
Database, accession number 700761). The gene has 12
exons spanning 23 kb of genomic DNA. Its 2.6-kb
mRNA codes for a 367–amino acid protein, cystinosin,
with homology to a 55.5-kD Caenorhabditis elegans
protein and to a yeast transmembrane protein, ERS1
(Town et al. 1998). Cystinosin has seven transmembrane
domains, a GY dipeptide near the C terminus, and eight
potential glycosylation sites. Eleven different mutations
in exons 3, 4, and 6–9 have been described, with no
correlation with clinical phenotype (Town et al. 1998).
The most common mutation, involving D17S829, con-
sists of a deletion extending from intron 10 upstream
x65 kb.
We report the CTNS mutations identified in an Amer-
ican-based population of 108 nephropathic cystinosis
patients, with concomitant phenotype correlations em-
ploying a clinical severity score. We trace the possible
origin of the 65-kb deletion, describe 18 previously un-
reported mutations, and delineate the mutations present
in cystinosis fibroblasts available from the Human Ge-
netic Mutant Cell Repository (HGMCR). Finally, we
identify the extent of CTNS gene expression in a sample
of cystinosis fibroblasts with various mutations.
Patients, Materials, and Methods
Patients
All patients or their parents gave informed consent to
participate in Institutional Review Board–approved pro-
tocols for the study of cystinosis at the National Insti-
tutes of Health (NIH) Clinical Center or the University
of Michigan Medical Center. Of 108 patient DNA sam-
ples, 102 were obtained from individuals who could po-
tentially provide clinical information; 5 samples were
from skin-biopsy fibroblasts stored at the NIH, and one
patient was unreachable. The subjects of this investi-
gation had classical nephropathic cystinosis, with onset
of their disease in early childhood, and came from
throughout the United States, Mexico, and Iceland.
Severity was determined in accordance with five pa-
rameters (table 1), each assigned a score of 1 (mild), 2
(average), or 3 (severe). The final severity score was the
mean of all applicable parameter scores, which were ob-
tained by history and chart review. Age at onset was the
age at the first clear appearance of symptoms. The leu-
kocyte cystine value refers to a level obtained prior to
initiation of cysteamine therapy. For a sample of 66 pa-
tients, the mean leukocyte cystine value, in nanomoles
half-cystine/milligram protein, was similar in three dif-
ferent age groups: 10.1 for 33 patients !5 years of age;
8.9 for 16 patients 5–15 years of age; and 12.2 for 17
patients 115 years of age. The normal value is !0.2 nmol
half-cystine/mg protein. The Fanconi syndrome index
offers an objective measure of the severity of Fanconi
syndrome, which is not influenced by cysteamine therapy
(Thoene et al. 1976; Gahl et al. 1987), by quantitating
the daily urinary excretion of 21 amino acids (Charnas
et al. 1991). Age at renal failure (i.e., dialysis or trans-
plantation) and nonrenal complications (i.e., myopathy,
swallowing difficulty, retinal blindness, CNS deteriora-
tion, and diabetes mellitus requiring insulin therapy) ap-
plied only to patients who had not received previous
cysteamine therapy. For 102 individuals for whom a clin-
ical history was available, a total of 277 parameters were
applicable, for a mean of 2.7 parameters/patient. At least
two parameters were required in order to assign a se-
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Table 2
Types of Mutations in Cystinosis Patients with Clinical
Data
Mutation Status No. of Patients
D17S829 deletion (homozygous) 50
W138X:
Homozygous 11
Heterozygous 3
Other mutations:a
Two alleles identified 18
One allele identified 6
No mutations identified 20
Total 108
a Includes 17 mutations not identified previously.
Figure 2 Gross map of the CTNS gene and upstream region. Five markers, D17S829, AA313583, T85505, and the PCR products of
exons 3 and 11, helped characterize deletions in cystinosis patients. The common 65-kb “large” deletion encompasses the first four markers,
with the 3′ breakpoint before exon 11. A smaller deletion, found in two patients and in fibroblast strain GM8, involves D17S829 and exon 3
but not exon 11 or markers AA313583 and T85505. The maximum size of the smaller deletion is shown.
verity score; 97 of 102 patients fulfilled this criterion.
All severity scores were determined without knowledge
of the patient’s mutation.
Cells
Cystinosis fibroblast strains (GM 8, 18, 46, 90, 304,
489, 706, 760, 2066, 2894, and 6966) were purchased
from the HGMCR or were obtained by skin biopsy after
informed consent. They were cultured as described else-
where (Tietze et al. 1989). Leukocytes were prepared
in accordance with procedures published previously
(Thoene et al. 1976; Steinherz et al. 1982). DNA was
extracted from whole blood, leukocytes, or fibroblasts,
by use of standard techniques (Sambrook et al. 1989).
PCR Detection of Homozygous D17S829 Deletions
By use of genomic DNA from leukocytes or fibroblasts
as a template, a 266-bp fragment of D17S829 in intron
3 of CTNS was amplified by PCR. The 25-ml reaction
volume contained 1# PCR buffer (GIBCO-BRL), 1.5
mM MgCl2, 200 mM dGTP, 200 mM dATP, 200 mM
dTTP, 200 mM dCTP, 0.2 mM primers, 2.5 U Taq DNA
polymerase, and 500 ng template DNA. After an initial
denaturation step at 94C for 4 min, PCR was conducted
for 30 cycles, each with a denaturation step at 94C for
30 s, annealing at 55C for 40 s, and extension at 72C
for 40 s. An elongation step at 72C for 10 min finalized
the procedure. The PCR products were electrophoresed
in 1% agarose and were stained with ethidium bromide.
As a positive control, DNA templates were demon-
strated, by PCR amplification (fig. 1A), to contain a
marker, SBG7, which is contained on YAC 767F9 of
chromosome 17 (McDowell et al. 1996) but which is
outside of the 65-kb deletion area since SBG7 was am-
plified in all cystinosis patients. The primers for this
marker were 5′-TTG CTG GGC TTA ATA CCT AGG
T-3′ and 5′-ATT GCT TTT GCT GTA TTC TAT AG-
3′. DNA templates that were not PCR amplified for
D17S829 were also analyzed for the extent of the de-
letion, by PCR amplification using four more primer
pairs, that is, exons 11 and 3 of CTNS and expressed
sequence tag (EST) markers AA313583 and T85505
(Town et al. 1998). Primers for T85505 were 5′-ATC
CTG TTT CAA ATG ATG ACC C-3′ and 5′-GTG AGA
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Figure 3 Distribution of 65-kb–deletion alleles. Eighty-two alleles of 48 CTNS deletion patients were assigned a most likely country of
origin, on the basis of family history. Each blackened circle represents one allele.
TAA ATA CGG CTC TCG-3′. Primers for AA313583
were 5′-TCT TGC TGC ATG TAC TCA GC-3′ and 5′-
TGG GAT ACA GAG TTC TCT TTG-3′.
SSCP Analysis
Exons 3–12 of CTNS were amplified from genomic
DNA (500 ng) in a volume of 25 ml, by use of a radio-
active PCR mixture consisting of 1# PCR buffer, 1.5
mM MgCl2, 200 mM dGTP, 200 mM dATP, 200 mM
dTTP, 200 mM dCTP, 1 mCi a[32P]-dCTP, 0.2 mM prim-
ers, and 2.5 U Taq DNA polymerase. After PCR am-
plification for 30 cycles, as stated above, 3 ml of PCR
product was treated with 10 ml of SSCP stop solution
and was denatured at 94C for 4 min. The samples then
were fractionated by electrophoresis at 4C for 6–8 h
on a 6% nondenaturing precast gel (Stratagene), with
1# Tris borate–EDTA (TBE), and were subjected to
autoradiography. An example of the results of SSCP
analysis of exon 7 is shown in figure 1B.
Base-Excision Sequence Scanning (BESS) T-Scan
Mutation Detection
Primers of exons 3–12 were 5′ end labeled by use of
g[32P]-ATP and T4 polynucleotide kinase (Epicenter), as
recommended by the company. After end labeling the
primers, exons 3–12 were amplified from genomic DNA
(500 ng), in a 25-ml reaction with 5 pmol of radioactive
primer, 5 pmol of nonradioactive primer, 1# PCR buf-
fer, 1.5 mM MgCl2, 200 mM dGTP, 200 mM dATP, 200
mM dTTP, 200 mM dCTP, 16 mM dUTP, and 2.5 U Taq
DNA polymerase. PCR conditions were identical to
those for SSCP. Eight microliters of PCR product was
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Table 3
Individual Mutations in American-Based Cystinosis Patients and Fibroblasts
Case Ethnicitya
Severity
Score mRNAb Exon(s) Base Change AA Change Stop Codon
Two mutations
identified:
1 Eng/Eng 2.7 ND 3 357delGACTc,d T7F 13
3 357delGACTc T7F 13
2 Ind/Ind 1.3  3 357delGACTc,d T7F 13
3 357delGACTc T7F 13
3 Ger/Ger 2.3 ND 3 357delGACTc,d T7F 13
3 357delGACTc T7F 13
4 Hol-Eng/Hun 2.5 ND 3 357delGACTc T7F 13
10 1033insCG V233A 253
5 ND ND  5 537del21bpd del67–73e )
5 537del21bp del67–73e )
6 Eng-Wal/Ger 2.0  5 537del21bpd del67–73e )
5 537del21bp del67–73e )
7 Nor-BrI/Ger-BrI 1.3  5 537del21bpd del67–73e )
5 537del21bp del67–73e )
8 Ger-BrI/Ger 2.0 ND 6 651delTCACd H105P 116
6 651delTCAC H105P 116
9 Fra/Eng 1.7 ND 7 721CrTc,d Q128X 128
7 721CrTc Q128X 128
10 Fra/Swe 2.0  8 845GrAd G169D )
8 845GrA G169D )
11 Aus-Swi/Den-Ire 2.0  8 883TrC W182R )
12 1367TCGTCTTCrA I343K 364
12 Ger/BrI 2.5 ND 8 900delGc,d 5′ Splice )
8 900delGc 5′ Splice )
13 Por/Por 1.7 ND 9 950delACGd D205del )
9 950delACG D205del )
14 Dom/Dom 2.0 ND 9 985insAd T216N 227
9 985insA T216N 227
15 Ita/Ita 1.5 ND 9 952GrA D205N )
11 1232GrA S298N )
16 Ger-Ire/ND 1.5  10 1035insC V233R 296
11 1261insG S310Q 364
17 Afr/Afr 1.3 ND 11 1209CrG Y290X 290
11 1209CrG Y290X 290
18 Kur-Afg/Eng-Fra 1.0  11 1261GrA G308R )
1–10 65-kb deletionf ) )
One mutation
identified:
19 Mex/Mex 2.7 ND 3 357delGACTc T7F 13
20 Eng-Ger/Eng 2.0  10 1080delC F247L 252
21 Pol-Ger/Eng 1.3 ND 10 1035insC V233R 296
22 ND ND  11 1253ArG D305G )
23 Ire-Swe/Ire-Fra 2.3 ND 11 1261GrA G308R )
24 Ita/Ita 1.7 ND 12 1354GrA G339R )
(continued)
subjected to excision/cleavage with 0.5 ml of BESS T-
scan excision-enzyme mix and 1# excision-enzyme buf-
fer (Epicenter), in a final volume of 10 ml. After incu-
bation of the mixture for 30 min at 37C, 5 ml of stop/
loading buffer (Epicenter) was added, and the reaction
mixture was heated at 75C for 5 min. The radiolabeled
cleavage products then were loaded onto a 5.5% Long
Ranger Precast Gel (Stratagene), with 1#TBE, and were
subjected to autoradiography for 48 h.
Direct DNA Sequencing
Sequencing was performed by use of a PCR-product
sequencing kit, from Amersham Life Science, Inc., and
5.5% Long Ranger Precast Gels, in accordance with the
manufacturer’s recommendations, or by automated se-
quencing at the University of Michigan core sequencing
facility.
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Table 3 (continued)
Case Ethnicitya
Severity
Score mRNAb Exon(s) Base Change AA Change Stop Codon
Fibroblasts:
GM8 1–10 65-kb deletiong ) )
1–10 65-kb deletion ) )
GM46 5 545delTCCTT I69R 73
5 545delTCCTT I69R 73
GM706 1–10 65-kb deletion ) )
1–10 65-kb deletion ) )
GM760 7 753GrAc W138X 138
7 753GrA W138X 138
GM2894h 1–10 65-kb deletion ) )
1–10 65-kb deletion ) )
a Eng  England; Ind  Indian subcontinent; Ger  Germany; Hol  Holland; Hun  Hungary; BrI  British Isles, that is, a mix of
England, Scotland, Wales, and Ireland; Wal  Wales; Nor Norway; Fra  France; Swe  Sweden; Aus  Austria; Swi  Switzerland; Den
 Denmark; Ire  Ireland; Por  Portugal; Dom  Dominican Republic; Ita  Italy; Afr  African American; Kur  Kurd; Afg Afghanistan;
Mex  Mexico; Pol  Poland; and ND  not determined.
b A plus sign () indicates present on northern, and a minus sign () indicates absent. ND  not determined.
c Previously reported by Town et al. (1998).
d Patient could be hemizygous for this mutation and could carry the 65-kb deletion.
e Amino acids ITILELP deleted.
f Genotype analysis indicated that the English/French mother carried the 65-kb deletion.
g This cell strain was negative for D17S829 and exon 3 but was positive for AA313583, T85505, and exon 11 markers.
h The donor of this SV40-transformed fibroblast strain was also an NIH patient and is included in the group of 50 deletion patients listed
in table 2 (Oshima et al. 1977).
Figure 4 Representative northern blot of patient RNA probed
with CTNS cDNA. RNA was from controls (lanes 1 and 5), a homo-
zygous 65-kb–deletion patient (lane 2), a patient (case 18) who is
compound heterozygous for the 65-kb deletion and G308R (lane 3),
and a patient (case 7) who is homozygous for an in-frame deletion of
amino acids 67–73 (lane 4). The cytinosin mRNA is ∼2.6 kb in size.
b-Actin mRNA helped to assess RNA loading; lane 1 served as a
control for lane 4, while lane 5 served as a control for lanes 2 and 3.
Subcloning and DNA Sequencing
After PCR amplification, PCR products were sub-
cloned into a pNoTA/T7 shuttle vector (5 Primer3
Prime). Four to six clones were selected and sequenced
by use of the universal20 M13/pUC DNA-sequencing
primer or the 24 M13/pUC reverse–DNA-sequencing
primer and a T7 Sequenase Quick-Denature Plasmid Se-
quencing kit (Amersham Life Science), in accordance
with the manufacterer’s recommendations.
Northern Blot Analysis
Total RNA (20 mg), isolated from cultured fibroblasts
by use of Trizol reagent (Life Technologies), was sepa-
rated on a 1.2% agarose/3% formaldehyde gel and was
blotted onto a Nytran nylon membrane (Schleicher &
Schuell) in the presence of 20# SSC. The blot was pre-
hydridized and then hybridized with ExpressHyb solu-
tion (Clontech), at 68C. The probe was human CTNS
cDNA, random-primer labeled with a[32P]-dCTP (Du-
Pont/New England Nuclear) and prepared by PCR am-
plification of exons 3–12 after reverse transcription of
total RNA. After hybridization, the blot was washed
several times with 2# SSC/0.05% SDS, at room tem-
perature, and once with 0.1# SSC/0.1% SDS, at 50C,
and was exposed to Kodak X-Omat AR film, with an
intensifying screen, for 24 h at 70C.
Genotype Analysis
Marker D17S829 was used for genotype analysis of
case 18 and her parents. PCR products were randomly
labeled with a[32P]-dCTP (DuPont/New England Nu-
clear). After PCR amplification, the products were de-
natured and the polymorphic alleles analyzed on 6%
denaturing gels.
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Table 4
CTNS Polymorphisms and Regional Distribution of Small Mutations
Domain
Total No. of
Amino Acids
Mutation
Number Mutation Names
Leader sequence 22 3 357delGATC; 371delT; 397delTG
Transmembrane 152 11 753GrA; 845GrA; 857delAC; 883TrC; 985insA; 1080delC;
1253ArG; 1261GrA; 1261insG; 1354GrA;
1367TCGTCTTCrA
Nontransmembrane 193 15 4791GrT; 537del21bp; 545delTCCTT; 622GrT; 651delTCAC;
721CrT; 900delG; 901-1GrC; 908del9bp; 950delACG;
952GrA; 1033insCG; 1035insC; 1209CrG; 1232GrA
Polymorphisms ) 5 669-5TrC; 843ArG, 10209ArG; 1214ArGa; 1299CrT
a This base change alters amino acid 292, from Lys to Arg, and could be pathologic; the other base changes are silent.
Results
DNA from 108 unrelated patients was analyzed by
three methods. First, it was tested for PCR-based am-
plification of D17S829 (fig. 1A). Fifty patients (46%)
were homozygously deleted for this marker (table 2).
DNA from the remaining patients was subjected to SSCP
analysis, followed by sequencing of abnormally migrat-
ing exons, and then was analyzed by Bess T scanning
to detect still unidentified mutations. These two methods
revealed mutations in 38 additional individuals (35%).
No mutations were found in the remaining 20 patients
(19%).
D17S829 Deletions
Of 50 patients deleted in D17S829, 48 also were de-
leted in EST markers AA313583 and T85505 and in
exon 3 (Town et al. 1998) but were positive for an exon
11 marker (see fig. 2). These 48 patients were considered
to have the common 65-kb European deletion. Two pa-
tients had a smaller deletion involving D17S829 and
exon 3 but were positive for AA313583, T85505, and
exon 11 (fig. 2). Both were of mixed European heritage
and had severity scores of 2.0.
The homozygous, 65-kb–deletion patients were ana-
lyzed for their ethnicity and disease severity. Of 96 alleles
in 48 patients, 82 were assigned a most likely nation of
origin, on the basis of family history. Thirty-eight (46%)
of the alleles were from Germany, 15 (18%) from Ire-
land, and 13 (16%) from England, but the mutation was
apparent in alleles derived from Iceland, Italy, and Spain
(fig. 3). The Spanish alleles were ascribed to an American
with Hispanic parents. For the 46 patients with the large
deletion and at least two clinical parameters to assess,
the mean  SD severity score was (stan-1.98 0.40
dard error 0.06), with a normal distribution around the
mean.
Our techniques did not rule out heterozygosity for the
65-kb deletion. Hence, some of the mutations noted be-
low as homozygous actually may be hemizygous, with
the second allele carrying the large deletion.
W138X Mutations
Fourteen patients exhibited a GrA substitution at nu-
cleotide 753 of exon 7, giving rise to a Trp r nonsense
mutation in codon 138 (table 2). Eleven were homo-
zygous for this mutation; their countries of origin in-
cluded Germany, France, and the British Isles. The se-
verity scores were either 2.0 or 2.3, with a mean  SD
of . The three patients heterozygous for2.13 0.16
W138X, in addition to being from Germany, France,
and the British Isles, had Scandinavian and Romanian
heritage. In these individuals, whose severity scores were
1.5, 2.0, and 2.3, no definitive second mutation could
be identified.
Other Mutations
Twenty-four patients had mutations other than
W138X and the 65-kb deletion (table 3). Three muta-
tions have been reported elsewhere (Town et al. 1998).
First, a homozygous GACT deletion resulting in a T7F
substitution and truncation at amino acid 13 was present
in three patients of English, Italian, and German heritage
(cases 1–3, table 3). The parents of case 2 were first
cousins. Heterozygous 357delGACT mutations were
also found in case 4 and in case 19, whose parents were
Mexican. Second, a homozygous CrT substitution in
nucleotide 721, which resulted in Q128X, was identified
in case 9 (table 3), a 29-year-old man with diabetes mel-
litus. Finally, a homozygous 900delG mutation, which
altered the 5′ splice site of intron 8, appeared in case 12,
a 17-year-old girl with a serum creatinine of 1.3 mg/dl
who had been treated with cysteamine from 15 mo of
age.
Seventeen new mutations were identified in patient
DNA (table 3). Three patients (cases 5–7) were homo-
zygous for a 21-bp deletion beginning at nucleotide 537
and eliminating seven amino acids, ITILELP. The pa-
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tients had different severity scores (e.g., 1.3 and 2.0) and
came from the British Isles and Germany.
Five patients displayed new, private, homozygous mu-
tations (table 3). Case 8 (651delTCAC) received cys-
teamine therapy from 1 year of age and had a serum
creatinine of 0.9 mg/dl at 13 years of age. Her mother
is German/Scottish/Irish, and her father is German. Case
10 (845GrA) had a serum creatinine of 1.1 mg/dl, at 8
years of age. Her father is French Canadian, and her
mother is Swedish and American Indian. Case 13
(950delACG), whose parents were Portuguese first cous-
ins, is now 20 years of age and had not received cys-
teamine prior to her renal allograft at 14 years of age.
Case 14 (985insA) is a 32-year-old man whose parents
are first cousins from the Dominican Republic. He never
had significant cysteamine therapy, but he had received
a renal allograft at 11 years of age and had developed
muscle wasting, hypophonia, and difficulty swallowing
in his early 20s. Case 17 (1209CrG) is a 26-year-old
African American who had received a kidney allograft
at 12 years of age, was diagnosed with cystinosis at 13
years of age, and, despite poor compliance with cys-
teamine therapy, has avoided the late complications of
cystinosis.
In five compound heterozygotes, both mutations
were identified. Case 4 carries the 357delGACT and
1033insCG mutations. This 11-year-old boy entered
chronic renal failure at 9 years of age, despite cysteamine
therapy from 8 mo of age. Case 11, a 25-year-old
woman, carries a W182R mutation and an 8-bp dele-
tion/A substitution. Case 15, 28 years of age, has milder
cystinosis, and both he and his twin brother also have
Klinefelter syndrome (Oberfield et al. 1981). The patient
did not enter renal failure until 15 years of age, despite
absence of cysteamine therapy, and he has had muscle
wasting and swallowing difficulty since 23 years of age.
He carries the unique mutations D205N and S298N.
Case 16 carries two new mutations, 1035insC and
1261insG. Because of good cysteamine therapy, her se-
rum creatinine was 0.8 mg/dl at 8 years of age and cur-
rently is 1.6 mg/dl, at 12 years of age. Case 18 had very
mild disease. Diagnosed because her older sister was af-
fected, she was treated with cysteamine from 6 mo of
age, and her current serum creatinine, at 9 years of age,
is 0.5 mg/dl. Her height is 128 cm (25th centile). The
patient’s father, who is Kurdish and Afghan, contributed
the G308R mutation, whereas her mother, who is Eng-
lish and French, contributed the typical 65-kb European
deletion.
Three new mutations, 1080delC, 1253ArG, and
1354GrA, were found on single alleles in cases 20, 22,
and 24, respectively. Case 21, a 17-year-old girl with
Polish, German, and English ancestry, is heterozygous
for 1035insC, a mutation that also is present in case 16
(table 3). Case 23 is heterozygous for 1261GrA, the
same mutation that case 18 carries on one allele.
Our techniques failed to identify mutations in 20 pa-
tients. Five apparent polymorphisms were found. Three
of these, which include one in an intron (6695TrC)
and two silent mutations (843ArG and 1299CrT),
were present in patients who also manifested two path-
ologic mutations. The 10209ArG change is specu-
lated to be nonpathologic because no consensus se-
quence has been described for the 9 position of the
intervening sequences. One base change, 1214ArG,
maintained the amino acid charge (K292R) and may
represent a true mutation, since it was not seen in normal
patients or in cystinosis patients in whom two other
mutations were identified.
HGMCR Fibroblast Mutations
Homozygous mutations were found in 5 of 11 fibro-
blast strains obtained from the HGMCR (table 3). Three
(GM8, GM706, and GM2894) were deleted in
D17S829, one (GM760) was homozygous for W138X,
and one (GM46) was homozygous for a new mutation,
545delTCCTT (I69R), which causes termination at co-
don 73. Two of the D17S829 deletions encompassed the
typical 65-kb span, but GM8 was positive for markers
AA313583 and T85505 and for exon 11.
Northern Blot Analysis
RNA was available from 20 patients and two cell
strains, for northern blot analysis. Five patients homo-
zygous for the typical 65-kb European deletion showed
no CTNS expression in fibroblasts (fig. 4), whereas var-
ious amounts ofCTNSmRNA were apparent in all other
samples studied (table 3 and fig. 4). These included 2
patients homozygous for W138X (data not shown), 10
patients with recognized CTNS mutations, and 3 pa-
tients in whom no mutation was found. CTNS mRNA
was present in cell strain GM2066 but not in GM8.
Discussion
Since the U.S. population is genetically heterogeneous,
it can illustrate the different mutations causing nephro-
pathic cystinosis, and we were able to identify mutations
in 81% of our patients. Some mutations correlated with
ethnicity and some did not. Forty-eight (44%) of 108
American-based patients were homozygous for the 65-
kb European deletion, compared with 23 (33%) of 70
patients in a French/British report (Town et al. 1998).
In both studies, only patients derived from European
countries were found to carry the 65-kb deletion, which
eliminates all CTNS mRNA (fig. 4) and causes typical
nephropathic cystinosis. Nearly half of the 65-kb–
deletion alleles in our patients appear to have arisen in
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Germany (fig. 3), although many derived from countries
surrounding Germany, and 28 (34%) of 82 arose from
the British Isles. The finding of two apparently unrelated
patients with homozygous deletions who are from Ice-
land, which has been genetically isolated since its early
settlement, suggests that the distribution of the 65-kb
deletion represents a founder effect. Since Germanic
tribes settled the British Isles in the late seventh century
and since the Vikings traveled from Norway, Scotland,
and Ireland to Iceland in 874 A.D., we speculate that the
65-kb deletion may have occurred initially in Germany,
prior to 700 A.D.; however, this hypothesis requires ver-
ification by haplotype analysis across the CTNS gene.
In addition to the 48 patients homozygous for the 65-
kb deletion, many of our patients may have one copy
of the deletion. Once the upstream deletion breakpoint
has been determined, a PCR-based test of heterozygosity
for the deletion can be developed; only the allele with
the 65-kb deletion will amplify when flanking primers
are used. We currently are pursuing this.
Two patients and one HGMCR cell strain (GM8) had
deletions that were smaller than the typical 65-kb de-
letion but that were still several kilobases in size. These
mutations may be identical to the smaller major deletion
reported by Town et al. (1998).
We found that W138X, a nonsense mutation associ-
ated with residual CTNS RNA expression, was present
in 25 (12%) of 216 patient alleles examined and in 2
(9%) of 22 HGMCR fibroblast alleles examined. Pa-
tients homozygous for this mutation had nephropathic
cystinosis of slightly worse than average severity and
were from Germany, France, or the British Isles.
Our identification of 18 new mutations in CTNS (ta-
ble 3) brings to 29 the total number of small CTNS
mutations reported. Whereas the 11 previously reported
small mutations (six deletions, three nonsense muta-
tions, and two splice-site mutations) result in truncated
proteins, we found two deletions and seven missense
mutations that did not alter the frame of the message.
Significant CTNS expression was associated with the
homozygous missense mutation G169D and with hemi-
zogosity for G308R. All seven missense mutations gave
rise to amino acid changes either inside a transmembrane
domain or in the first amino acid prior to a transmem-
brane domain. Similarly, in the NKCC2 gene responsible
for Bartter syndrome, 8 of the 10 missense mutations
identified were inside or within a few amino acids of
transmembrane domains (Vargas-Poussou et al. 1998).
For CTNS, Q128X is at the border of transmembrane
domain 1, D205 and D205N are at the border of trans-
membrane domain 3, and S298N is at the border of
transmembrane domain 6. When one patient who was
compound heterozygous for D205N and S298N was
included, the severity scores associated with these mu-
tations were within the range 1.5–1.7 (table 3), which
indicates that these mutations may cause relatively mild
disease. Of the seven CTNS missense mutations, four
(G169D, D205N, D305G, and G308R) involve amino
acids conserved from yeast to C. elegans to humans, and
two (S298N and G339R) affect amino acids conserved
between C. elegans and humans. The conservation of
these amino acids, as well as the charge difference as-
sociated with the base changes, indicates that the alter-
ations are mutations rather than simply polymorphisms.
Two in-frame deletions, D205 and 537del21bp, were
associated with severity scores of 1.7 and 1.3–2.0, re-
spectively. The relatively mild disease may be due to
frame preservation. Moreover, although D205 alters a
conserved aspartic acid, it occurs just before a trans-
membrane domain, which may mitigate its phenotypic
impact. The 537del21bp mutation inteferes with a po-
tential N-linked glycosylation site, but the N66 residue
may not be routinely glycosylated; the homozygous mu-
tation does allow for some CTNS expression (fig. 4).
We also caution that severity scores based on only two
or three parameters are most useful when a large group
of patients with the same mutation is assessed.
The CTNS mutations are distributed relatively evenly
across exons 3–12 (table 3) and across the different
structural domains (table 4). Three distinct mutations
arose in the 22–amino acid leader sequence, compared
with 11 in the seven transmembrane regions comprising
152 amino acids and 15 in the eight nontransmembrane
regions comprising 193 amino acids. The C-terminal
lysosomal targeting signal was not mutated in any pa-
tient. Similar severity scores were associated with mu-
tations in the different regions.
A few comments on our patients’ mutations are war-
ranted. First, we found 357delGACT in the homozygous
state among three nationalities (English, German, and
Indian), which confirms the report of Town et al. (1998)
that this mutation arose on different continents. In ad-
dition, the 1261GrA (G308R) mutation was associated,
in the heterozygous state, with a Kurdish/Afghan parent
(case 18) and an Irish/Swedish/French family (case 23).
Hence, 357delGACT and G308R appear to be recurrent
mutations. Moreover, 357delGACT was associated with
widely variable disease severities (cases 1–3, table 3),
which indicates that ancillary genes can influence the
severity of cystinosis.
Second, two small regions of CTNS each display mul-
tiple mutations, namely, 950delACG/950GrA and
1261GrA/1261insG. These regions may prove to be
somewhat mutation prone. Third, the large number of
CTNS deletions—that is, 10 in addition to the 2 major
deletions—supports the contention that this area of
chromosome 17p is susceptible to deletions. Charcot-
Marie-Tooth disease type 1A, hereditary neuropathy
with liability to pressure palsies, Smith-Magenis syn-
drome, and Miller-Dieker syndrome are all caused by
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deletions or duplications between 17p13 and 17p11.2
(Stratton et al. 1984; Smith et al. 1986; Reiter et al.
1996). Sequence data forCMT1A,HNPP, and SMS have
implicated unequal crossing over between homologous
repeats as the mechanism for these rearrangements (Rei-
ter et al. 1996), although altered activity of a “mariner”
transposon–like element at 17p11.2 also could contrib-
ute (Reiter et al. 1996). Interestingly, 17p13 is the site
of a large olfactory receptor–gene cluster produced by
multiple intrachromosomal duplications (Glusman et al.
1996). When the exact breakpoints of the large CTNS
deletion have been determined, the mechanism for the
high frequency of deletions in this area may be revealed.
Oral cysteamine will remain the mainstay of cystinosis
therapy, and both postnatal and prenatal diagnosis will
continue to depend heavily on leukocyte cystine meas-
urements; however, molecular diagnosis of nephropathic
cystinosis now will take its place in cases involving dif-
ficulty in the preparation of leukocytes for assay, equiv-
ocal results, or heterozygote detection.
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